(Reuters) – Johnson & Johnson is close to reaching a settlement with the U.S. Justice Dept. over allegations it promoted its antipsychotic Risperdal for unapproved uses that could cost the healthcare conglomerate at least $ 1.5 billion, the Wall Street Journal reported on Wednesday.
- International Marketing Expert Nitin Chhoda Reveals the Benefits Offered By Physical Therapy Software to Physical Therapy Clinics
- Marketing Expert, Nitin Chhoda, Recently Announces How EMRs Offer Clinicians Flexibility and Multiple Methods of Collection in the 21st Century
- FDA halts J&J study of pain drug over safety
- Anti-AIDS groups hail drug but worry over cost
- Court to decide lawsuit over generic drug labels